Valion Bio, Inc. (VBIO)
| Market Cap | 2.39M -36.7% |
| Revenue (ttm) | n/a |
| Net Income | -13.58M |
| EPS | -7.91 |
| Shares Out | 3.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 62,714 |
| Open | 0.7500 |
| Previous Close | 0.7500 |
| Day's Range | 0.7200 - 0.7700 |
| 52-Week Range | 0.6001 - 5.6000 |
| Beta | 1.79 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 14, 2026 |
About VBIO
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company’s pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in Apr... [Read more]
Financial Performance
Financial StatementsNews
Valion Bio Transcript: AGM 2026
The meeting marked the first under the new company name and focused on executing a biopharma strategy. All eight shareholder proposals, including director election and share issuances, were approved, with strong emphasis on clinical development and governance.
VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME
Cross-Agency Discussion Highlights Interest in Oral Formulation as Field-Deployable Medical Countermeasure SAN ANTONIO, May 19, 2026 /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO), a late-stage innat...
Valion Bio’s Velocity Bioworks licenses LarmorBio’s BioScan-NMR platform
Valion Bio’s (VBIO) wholly owned subsidiary, Velocity Bioworks, has entered into an exclusive commercial development and license agreement with LarmorBio for LarmorBio’s BioScan-NMR platform, a next-g...
Valion Bio reports Q1 EPS ($2.23) vs. ($2.52) last year
Cash and cash equivalents at March 31, 2026 totaled $7.2M vs. $12.6M at December 31, 2025. The company continues to evaluate capital alternatives to support continued execution against pipeline, regul...
Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform
First Commercial Installation Targeted for July 2026 in San Antonio; Strategic Reference Site Positions Velocity Bioworks at the Forefront of Next-Generation NMR-Based Diagnostics SAN ANTONIO, May 14,...
Valion Bio Earnings Call Transcript: Q1 2026
Q1 2026 saw a major transformation with the launch of Velocity Bioworks, a significant rise in operating expenses, and a shift to federally funded entolimod development. Near-term revenue is expected from CDMO operations, with key clinical and regulatory milestones targeted for 2026.
Valion Bio Earnings release: Q1 2026
Valion Bio released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Valion Bio Quarterly report: Q1 2026
Valion Bio has published its Q1 2026 quarterly earnings report on May 14, 2026.
VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
First Reporting Quarter as Valion Bio Marked by Continued Advancement of the Entolimod Platform, Broader Government Engagement, and Continued Integration of Velocity Bioworks Conference Call to be Hel...
Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026
SAN ANTONIO, Texas, May 11, 2026 /PRNewswire/ -- Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a clinical-stage immunotherapeutics company developing Entolimod™ for Acute Radi...
Valion Bio Celebrates Grand Opening of Velocity Bioworks Biomanufacturing Facility in San Antonio, Anchoring Domestic Production of Entolimod™
Senator John Cornyn recognizes facility's role in advancing radiation countermeasures for cancer patients and U.S. warfighters; Mayor Gina Ortiz Jones, Office of Senator Cornyn, and Velocity Bioworks ...
Valion Bio receives first study protocol under agreement with NIAID
Valion Bio (VBIO) announced it has received the first study protocol under its previously announced non-clinical evaluation agreement with the National Institute of Allergy and Infectious Diseases, a ...
VALION BIO RECEIVES FIRST FDA-PRECEDENT STUDY PROTOCOL FROM NIAID FOR ENTOLIMOD™; FEDERAL AGENCY TO FULLY FUND BLA-ENABLING IN VIVO PROGRAM AND CO-NAVIGATE FDA SUBMISSION
Initial Study to Evaluate Entolimod™ for Gastrointestinal Tissue Preservation in Partial-Body Acute Radiation Syndrome — an Indication for Which No Currently Approved or Stockpiled Countermeasure Has ...
Valion Bio names Melinda Lackey as General Counsel
Valion Bio (VBIO) announced the appointment of Melinda Lackey as General Counsel and Senior Vice President of Legal Affairs. Lackey brings nearly two decades of combined scientific and legal experienc...
Valion Bio Appoints Melinda Lackey as General Counsel
Seasoned Biopharmaceutical Attorney with Deep IP, Clinical-Stage, and Nasdaq Public Company Experience Joins Leadership Team SAN ANTONIO, May 4, 2026 /PRNewswire/ -- Valion Bio, Inc. (formerly Tivic H...
Valion Bio Proxy statement: Proxy filing
Valion Bio filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
VALION BIO BRIEFS PENTAGON LEADERSHIP ON ENTOLIMOD™ FOR ACUTE RADIATION SYNDROME
Company Presented Entolimod™ from its TLR5 Platform to the Deputy Assistant Secretary of Defense for Nuclear, Chemical, and Biological Defense Programs SAN ANTONIO, April 28, 2026 /PRNewswire/ -- Vali...
Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model
Ticker Symbol to Change from TIVC to VBIO Effective April 28, 2026; Company Advancing Entolimod™ Toward BARDA Funding and Strategic National Stockpile Procurement While Velocity Bioworks CDMO Builds I...
Valion Bio Proxy statement: Proxy filing
Valion Bio filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
Tivic Health Selected to Present Entolimod™ as a Radiation Countermeasure and its Plans for an Oral Transmucosal Program to the Department of War Tech Watch Program on May 7th
SAN ANTONIO, April 15, 2026 /PRNewswire/ -- Tivic Health Systems, Inc. (Nasdaq: TIVC), a clinical-stage immunotherapeutics company, today announced it has been selected to present at the U.S. Departme...
Valion Bio Registration statement: Registration filing
Valion Bio filed a registration statement on April 13, 2026, providing details about a securities offering with the SEC.
Valion Bio Transcript: Emerging Growth Conference 91
The company is advancing late-stage immune therapies, with Entolimod leading in ARS and neutropenia. Phase III data supports regulatory filings, and government partnerships may enable stockpile inclusion. Key milestones are expected within 18-24 months.
Tivic Receives Formal Request for Information from Ukrainian Ministry of Health Regarding Strategic Stockpiling of Entolimod
SAN ANTONIO, TX / ACCESS Newswire / March 31, 2026 / Tivic Health Systems, Inc. (Nasdaq:TIVC), a clinical-stage immunotherapeutics company, today announced it has received a formal Request for Informa...
Tivic CEO To Present at the Upcoming Emerging Growth's April 2026 Virtual Conference
Presentation will Cover Recent Corporate Milestones Including Securing Agreement with NIAID SAN ANTONIO, TX / ACCESS Newswire / March 27, 2026 / Tivic Health® Systems, Inc. (Nasdaq:TIVC), a clinical-s...
Tivic Secures NIAID Non-Clinical Evaluation Agreement for Entolimod, Targeting Gastrointestinal Acute Radiation Syndrome
Armed Forces Radiobiology Research Institute (AFRRI) Will Conduct the Gastrointestinal Acute Radiation Syndrome (GI-ARS) Study SAN ANTONIO, TX / ACCESS Newswire / March 26, 2026 / Tivic Health Systems...